immunomodulation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-06. Anything still debated is marked as such rather than presented as settled.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
From 2014, biosimilars were manufactured by several companies and sold at a lower price than before patent expiry. In 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia. In 2016, Indian drugmaker Torrent Pharmaceuticals launched its biosimilar for adalimumab, called Adfrar. It is the second generic biosimilar of adalimumab. In September 2016, the FDA approved Amgen's biosimilar adalimumab-atto, sold under the brand name Amjevita. In August 2017, the FDA approved German pharmaceutical company Boehringer Ingelheim's biosimilar, Cyltezo. In 2017, the biosimilars Amgevita, Solymbic, Imraldi, and Cyltezo were approved for use in the European Union. In 2018, the biosimilars Halimatoz, Hefiya, Hyrimoz, and Hulio were approved for use in the European Union. From 2018, Adalimumab biosimilars became available in the European Union, allowing the National Health Service to make record-breaking cost-savings, as this is the single most expensive drug used in NHS hospitals, costing more than £400 million a year for about 46,000 patients. In October 2018, adalimumab-adaz (Hyrimoz) was approved for use in the United States. In April 2019, Idacio and Kromeya were approved for use in the European Union. In July 2019, adalimumab-bwwd (Hadlima), produced by Samsung Bioepsis, was approved for use in the US. In November 2019, adalimumab-afzb (Abrilada) was approved in the United States. It is the 25th biosimilar approved by the FDA.
== See also == List of acts of the 117th United States Congress Procedures of the U.S. Congress List of United States federal legislation List of executive actions by Joe Biden List of impeachment resolutions introduced against Donald Trump
In the 21st century, the university has seen the construction of a new student union, two dedicated parking garages, the Earl S. Richardson Library, the Dixon Research Center, the Communications Building, and the Center for the Built Environment and Infrastructure Studies. The Carl J. Murphy Fine Arts Center is also the home of the James E. Lewis Museum of Art. In September 2012, Morgan State opened the Center for the Built Environment and Infrastructure Studies (CBEIS) which houses the School of Architecture and Planning, School of Transportation Studies, and the School of Engineering. In 2020, MacKenzie Scott donated $40 million to Morgan State. The following year, Calvin E. Tyler Jr. donated $20 million to endow scholarships. In 2025, MacKenzie Scott donated an additional $63 million to Morgan State, the largest donation in the history of the institution. The National Trust for Historic Preservation has designated Morgan State University as a National Treasure, the only such honor for a college or university campus in the United States. The neighboring Morgan Park Historic District was listed on the National Register of Historic Places in 2020.
Sources: en.wikipedia.org
== Benefits over conventional filtration == A higher overall liquid removal rate is achieved by the prevention of filter cake formation Process feed remains in the form of a mobile slurry, suitable for further processing Solids content of the product slurry may be varied over a wide range It is possible to fractionate particles by size Tubular pinch effect
==== Analysis of biological fluids ==== The GC-EI-MS can be incorporated for the analysis of biological fluids for several applications. One example is the determination of thirteen synthetic pyrethroid insecticide molecules and their stereoisomers in whole blood. This investigation used a new rapid and sensitive electron ionization-gas chromatography–mass spectrometry method in selective ion monitoring mode (SIM) with a single injection of the sample. All the pyrethroid residues were separated by using a GC-MS operated in electron ionization mode and quantified in selective ion monitoring mode. The detection of specific residues in blood is a difficult task due to their very low concentration since as soon as they enter the body most of the chemicals may get excreted. However, this method detected the residues of different pyrethroids down to the level 0.05–2 ng/ml. The detection of this insecticide in blood is very important since an ultra-small quantity in the body is enough to be harmful to human health, especially in children. This method is a very simple, rapid technique and therefore can be adopted without any matrix interferences. The selective ion monitoring mode provides detection sensitivity up to 0.05 ng/ml. Another application is in protein turnover studies using GC-EI-MS. This measures very low levels of d-phenylalanine which can indicate the enrichment of amino acid incorporated into tissue protein during studies of human protein synthesis.
=== Joint arrest operation and extradition of Saab === Maduro's industry minister Alex Saab, released from the United States in 2023 in a prisoners exchange with Venezuela, was dismissed from his role on 16 January by acting president Delcy Rodríguez. She merged the industry and the commerce ministry. According to US officials, Saab and the head of the Globovisión TV network Raúl Gorrín were arrested in February by Bolivarian National Intelligence Service (SEBIN) in a joint operation between Venezuela and the United States. They are expected to be extradited to the United States. The Venezuelan government announced on 16 May that Saab was deported to the United States. He is a possible witness against the prosecution of Nicolás Maduro.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.